Cosmo Pharmaceuticals SpA (COPN), the Italian drugmaker that ended a pact to merge with Salix Pharmaceuticals Ltd. (SLXP) of the U.S., plans to move its management to Ireland to benefit from the country’s business environment.
Cosmo, which is listed in Switzerland, said it will hold an extraordinary shareholders meeting on Nov. 14 about the move. It plans to build a new manufacturing plant and tap professional skills in Ireland. The Lainate, Italy-based company also plans to move its registered office to Luxembourg because of that country’s corporate law advantages, its said in a statement today.
Help employers find you! Check out all the jobs and post your resume.
